91 research outputs found
Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis
No full textThe p7 protein of hepatitis C virus (HCV) is a viroporin that is dispensable for viral genome replication but plays a critical role in virus morphogenesis. In this study, we generated a JFH1-based intergenotypic chimeric genome that encoded a heterologous genotype 1b (GT1b) p7. The parental intergenotypic chimeric genome was nonviable in human hepatoma cells, and infectious chimeric virions were produced only when cells transfected with the chimeric genomes were passaged several times. Sequence analysis of the entire polyprotein-coding region of the recovered chimeric virus revealed one predominant amino acid substitution in nonstructural protein 2 (NS2), T23N, and one in NS5B, K151R. Forward genetic analysis demonstrated that each of these mutations per se restored the infectivity of the parental chimeric genome, suggesting that interactions between p7, NS2, and NS5B were required for virion assembly/maturation. p7 and NS5B colocalized in cellular compartments, and the NS5B mutation did not affect the colocalization pattern. The NS5B K151R mutation neither increased viral RNA replication in human hepatoma cells nor altered the polymerase activity of NS5B in an in vitro assay. In conclusion, this study suggests that HCV NS5B is involved in virus morphogenesis.Hamed Gouklani, Rowena A. Bull, Claudia Beyer, Fasséli Coulibaly, Eric J. Gowans, Heidi E. Drummer, Hans J. Netter, Peter A. White and Gholamreza Haqshena
Freiheit und Bindung in der Bibelillustration der Renaissance eine ikonographische Studie zu Hans Holbeins d. J. "Icones"
No full text
Nouveaux modeles d'enseignement superieur et egalite des chances: prospectives internationals = New models of higher education and equality of opportunity: international perspectives. Studies: Education Series No. 6
No full text
Temperature dependence of the Ebar-]2abar far-infrared absorption line of excited chromium ions in ruby
No full textBy using far-infrared laser spectroscopy we have studied the temperature dependence of the absorption that is due to transitions between the E¯(2E) and 2A¯(2E) levels of excited Cr3+ ions in ruby. From the temperature dependence of the linewidth we determined the inhomogeneous and the homogeneous contributions to line broadening. From the homogeneous width the lifetime of the 2A¯ level was obtained. We found that, for emperatures up to 70 K, the lifetime is due mainly to one-phonon relaxation, whereas at higher temperatures another relaxation process, probably a two-phonon Raman process, becomes strong
Signalome-wide assessment of host cell response to hepatitis C virus
No full textHost cell signalling during infection with intracellular pathogens remains poorly understood. Here we report on the use of antibody microarray technology to detect variations in the expression levels and phosphorylation status of host cell signalling proteins during hepatitis C virus (HCV) replication. Following transfection with HCV RNA, the JNK and NF-kappa B pathways are suppressed, while the JAK/STAT5 pathway is activated; furthermore, components of the apoptosis and cell cycle control machineries are affected in the expression and/or phosphorylation status. RNAi-based hit validation identifies components of the JAK/STAT, NF-kappa B, MAPK and calcium-induced pathways as modulators of HCV replication. Selective chemical inhibition of one of the identified targets, the JNK activator kinase MAP4K2, does impair HCV replication. Thus this study provides a comprehensive picture of host cell pathway mobilization by HCV and uncovers potential therapeutic targets. The strategy of identifying targets for anti-infective intervention within the host cell signalome can be applied to any intracellular pathogen.Australian Cancer Research Foundation (ACRF); Victorian Department of Industry, Innovation and Regional Development (DIIRD); Australian Phenomics Network (APN); Australian Government's Education Investment Fund through the Super Science Initiative; Australasian Genomics Technologies Association (AGTA); Brockhoff Foundation; Peter MacCallum Cancer Centre Foundation; EU (ERC HEPCAR); EU (H2020 HEPCENT); NIH [U19-AI123862]; Australian Centre for HIV and Hepatitis Virology Research (ACH2)SCI(E)ARTICLE
Penicillamine Revisited: Historic Overview and Review of the Clinical Uses and Cutaneous Adverse Effects
No full textPenicillamine is a well-known heavy metal chelator, classically used in the treatment of Wilson disease, rheumatoid arthritis, and cystinuria. From a dermatologic standpoint, penicillamine was found to be useful in the treatment of systemic sclerosis. The successful therapeutic uses of penicillamine have been hindered by its numerous adverse effects, both cutaneous and extra-cutaneous. It is a unique drug since it provokes a diversity of dermatologic manifestations that include (1) acute hypersensitivity reactions, (2) dermopathies characterized by elastic fiber abnormalities including elastosis perforans serpiginosa and pseudo-pseudoxanthoma elasticum, (3) autoimmune disorders such as pemphigus and penicillamine-induced lupus erythematosus-like syndrome, and (4) miscellaneous dermatoses that result from undefined mechanisms. These cutaneous adverse effects may correlate with the dosage and duration of penicillamine therapy as well as the disease being treated. © 2013 Springer International Publishing Switzerland.Abraham EP, 1943, NATURE, V151, P107, DOI 10.1038-151107a0; AMICHAI B, 1994, ISRAEL J MED SCI, V30, P667; Atzori Laura, 2011, Dermatol Online J, V17, P3; Bacon PA, 1976, QJM, V80, P661; BARDACH H, 1979, J CUTAN PATHOL, V6, P243, DOI 10.1111-j.1600-0560.1979.tb01131.x; Becuwe C, 2005, DERMATOLOGY, V210, P60, DOI 10.1159-000081487; BEER WE, 1967, BRIT J DERMATOL, V79, P123, DOI 10.1111-j.1365-2133.1967.tb11471.x; BEER WE, 1966, LANCET, V2, P1337; BENNETT RA, 1967, ARCH INTERN MED, V120, P374, DOI 10.1001-archinte.120.3.374; BERGMAN R, 1987, ARCH DERMATOL, V123, P1127, DOI 10.1001-archderm.123.9.1127; BERTRAND JL, 1981, THERAPIE, V36, P333; BialyGolan A, 1996, J AM ACAD DERMATOL, V35, P732, DOI 10.1016-S0190-9622(96)90729-X; Bienaime F, 2007, AM J KIDNEY DIS, V50, P821, DOI 10.1053-j.ajkd.2007.05.026; BIRD ED, 1974, POSTGRAD MED J, V50, P73; Bischoff L, 2008, INT J DERMATOL, V47, P29, DOI 10.1111-j.1365-4632.2007.03544.x; BOLOGNIA JL, 1992, DERMATOLOGY, V184, P12; BOULDING JE, 1957, LANCET, V2, P985; Brem S, 2005, NEURO-ONCOLOGY, V7, P246, DOI 10.1215-S1152851704000869; Brem S., 1999, CANC CONTROL, V6, P436; Brenner S, 1998, CLIN DERMATOL, V16, P393, DOI 10.1016-S0738-081X(98)00010-8; BROWN MD, 1987, ARCH DERMATOL, V123, P1119, DOI 10.1001-archderm.123.9.1119; Brozyna AA, 2008, INT J CANCER, V123, P1448, DOI 10.1002-ijc.23664; BURGE S, 1988, CLIN EXP DERMATOL, V13, P255, DOI 10.1111-j.1365-2230.1988.tb00693.x; CAMUS J-P, 1981, Journal of Rheumatology, V7, P80; Capell HA, 1986, P 3 WORLD C CLIN PHA; CASPI D, 1982, RHEUMATOL REHABIL, V21, P218, DOI 10.1093-rheumatology-21.4.218; Cetkovska P, 2003, J AM ACAD DERMATOL, V49, P1157, DOI 10.1016-S0190-9622(03)00441-9; Chappel R, 1996, CLIN RHEUMATOL, V15, P86, DOI 10.1007-BF02231694; Clements PJ, 2000, ARTHRITIS RHEUM, V43, P2445, DOI 10.1002-1529-0131(200011)43:112445::AID-ANR113.0.CO;2-Q; Clements PJ, 1999, ARTHRITIS RHEUM, V42, P1194, DOI 10.1002-1529-0131(199906)42:61194::AID-ANR163.0.CO;2-7; Coatesworth AP, 1998, J CLIN PATHOL, V51, P169; Corrigan JJ, 2003, HAEMOPHILIA, V9, P64, DOI 10.1046-j.1365-2516.2003.00676.x; COYLE HE, 1980, ACTA DERM-VENEREOL, V60, P181; Davis W., 1977, ARCH DERMATOL, V113, P976; DAWKINS R L, 1981, Journal of Rheumatology, V7, P56; Degos R, 1969, Bull Soc Fr Dermatol Syphiligr, V76, P751; DELAMERE JP, 1983, ANN RHEUM DIS, V42, P500, DOI 10.1136-ard.42.5.500; Derk CT, 2003, J RHEUMATOL, V30, P1616; Derk CT, 2008, BRIT J DERMATOL, V158, P1063, DOI 10.1111-j.1365-2133.2008.08452.x; DESILVA RN, 1992, CLIN RHEUMATOL, V11, P216, DOI 10.1007-BF02207960; EPLER GR, 1979, JAMA-J AM MED ASSOC, V242, P528, DOI 10.1001-jama.242.6.528; EPSTEIN O, 1979, NEW ENGL J MED, V300, P274, DOI 10.1056-NEJM197902083000602; FALANGA V, 1990, ARCH DERMATOL, V126, P609, DOI 10.1001-archderm.126.5.609; FARRINGTON ML, 1993, J RHEUMATOL, V20, P128; FERNANDES L, 1977, ANN RHEUM DIS, V36, P94, DOI 10.1136-ard.36.1.94; GARLEPP MJ, 1983, BRIT MED J, V286, P1442; Godar JM, 1992, ARCH DERMATOL, V128, P980; GODAR JM, 1992, ARCH DERMATOL, V128, P977; GREER KE, 1976, ARCH DERMATOL, V112, P1267, DOI 10.1001-archderm.112.9.1267; GRISANTI MW, 1989, SEMIN ARTHRITIS RHEU, V19, P151, DOI 10.1016-0049-0172(89)90027-9; Gupte A, 2009, CANCER TREAT REV, V35, P32, DOI 10.1016-j.ctrv.2008.07.004; Habib GS, 2006, EUR J INTERN MED, V17, P343, DOI 10.1016-j.ejim.2006.03.001; HARRIS ED, 1966, LANCET, V2, P996; HAY KD, 1978, ORAL SURG ORAL MED O, V45, P385, DOI 10.1016-0030-4220(78)90524-8; Hill VA, 2000, BRIT J DERMATOL, V142, P560, DOI 10.1046-j.1365-2133.2000.03379.x; HUSKISSO.EC, 1974, POSTGRAD MED J, V50, P59; Iozumi Ken, 1997, Journal of Dermatology (Tokyo), V24, P458; JAIN S, 1977, LANCET, V1, P831; Jan V, 1999, ANN DERMATOL VENER, V126, P153; JIMENEZ SA, 1991, J RHEUMATOL, V18, P1496; Kato Y, 1997, J NEUROL SCI, V146, P85, DOI 10.1016-S0022-510X(96)00265-1; KAY A, 1986, BRIT J RHEUMATOL, V25, P193; Kaya TI, 2002, PEDIATR DERMATOL, V19, P359, DOI 10.1046-j.1525-1470.2002.00104.x; Klingenberg SL, 2006, COCHRANE DB SYST REV; KORMAN NJ, 1991, J INVEST DERMATOL, V96, P273, DOI 10.1111-1523-1747.ep12464471; KOVALYOV VM, 1989, VESTN DERMATOL VENER, P13; KUKOVETZ WR, 1983, J RHEUMATOL, V10, P90; KYOGOKU K, 1982, YAKUGAKU ZASSHI, V102, P322; Le Saux O, 2000, NAT GENET, V25, P223; LEVER LR, 1985, BRIT J DERMATOL, V113, P88, DOI 10.1111-j.1365-2133.1985.tb13057.x; LEVY RS, 1983, J AM ACAD DERMATOL, V8, P548, DOI 10.1016-S0190-9622(83)70062-9; Lewis BKH, 2009, J AM ACAD DERMATOL, V60, P700, DOI 10.1016-j.jaad.2008.09.018; LINARES A, 1979, LANCET, V2, P43; Herrero JL, 2012, GASTROENT HEPAT-BARC, V35, P704, DOI 10.1016-j.gastrohep.2012.03.008; Manzini CU, 2012, CLIN RHEUMATOL, V31, P183, DOI 10.1007-s10067-011-1866-3; MARSDEN RA, 1976, BRIT MED J, V2, P1423; MARTIHUGUET T, 1989, ARCH OPHTHALMOL-CHIC, V107, P1115; MARTINEZOSUNA P, 1991, SEMIN ARTHRITIS RHEU, V21, P110, DOI 10.1016-0049-0172(91)90044-Z; MAYOU BJ, 1981, BRIT J DERMATOL, V105, P87, DOI 10.1111-j.1365-2133.1981.tb00887.x; Medsger TA, 2001, SCAND J RHEUMATOL, V30, P192; MEHREGAN AH, 1968, ARCH DERMATOL, V97, P381, DOI 10.1001-archderm.97.4.381; MOYNAHAN EJ, 1973, LANCET, V1, P428; MUTASIM DF, 1993, DERMATOL CLIN, V11, P463; Nagao K, 2005, CLIN EXP DERMATOL, V30, P43, DOI 10.1111-j.1365-2230.2004.01655.x; Nagler R, 2010, ONCOLOGY-BASEL, V78, P12, DOI 10.1159-000287967; NETTER P, 1987, CLIN PHARMACOKINET, V13, P317; NIMNI ME, 1977, P ROY SOC MED, V70, P65; Ogata K, 2001, BRIT J DERMATOL, V144, P421, DOI 10.1046-j.1365-2133.2001.04043.x; OLIVER I, 1972, J AMER MED ASSOC, V220, P588; PASS F, 1973, ARCH DERMATOL, V108, P713, DOI 10.1001-archderm.108.5.713; PEGUM JS, 1977, BRIT MED J, V1, P1473; Penas PF, 1997, J AM ACAD DERMATOL, V37, P121, DOI 10.1016-S0190-9622(97)70224-X; PERRETT D, 1981, Journal of Rheumatology, V7, P41; PETERSEN J, 1978, SCAND J RHEUMATOL, V7, P113; PEYRI J, 1986, J AM ACAD DERMATOL, V14, P681, DOI 10.1016-S0190-9622(86)80459-5; Phelps DL, 2001, COCHRANE DB SYST REV; Pinter R, 2004, AM J MED GENET A, V128A, P294, DOI 10.1002-ajmg.a.10871; Popadic S, 2009, AM J CLIN DERMATOL, V10, P36, DOI 10.2165-0128071-200910010-00006; Poulas K, 2012, J NEUROIMMUNOL, V250, P94, DOI 10.1016-j.jneuroim.2012.05.011; PRICE RG, 1986, AM J DERMATOPATH, V8, P314, DOI 10.1097-00000372-198608000-00007; Qiao SX, 2012, APOPTOSIS, V17, P1079, DOI 10.1007-s10495-012-0746-x; RASMUSSEN HB, 1989, J CUTAN PATHOL, V16, P154, DOI 10.1111-j.1600-0560.1989.tb00031.x; Rath Namita, 2005, Indian J Dermatol Venereol Leprol, V71, P182; Rayatt S, 2006, J PLAST RECONSTR AES, V59, P1127, DOI 10.1016-j.bjps.2006.01.010; Rimbaud P, 1973, Med Chir Dig, V2, P3; RIMBAUD P, 1970, Bulletin de la Societe Francaise de Dermatologie et de Syphiligraphie, V77, P484; RODNAN G P, 1981, Journal of Rheumatology, V7, P116; Roest MAB, 2003, BJU INT, V91, P427, DOI 10.1046-j.1464-4096.2003.04042.x; Rosen LB, 2005, CUTIS, V76, P49; RUOCCO V, 1991, INT J DERMATOL, V30, P307, DOI 10.1111-j.1365-4362.1991.tb03867.x; Santa Cruz D J, 1981, Am J Dermatopathol, V3, P85, DOI 10.1097-00000372-198100310-00012; SAVAGE A, 1980, BRIT J EXP PATHOL, V61, P471; SCHRAEDE.PL, 1972, ARCH NEUROL-CHICAGO, V27, P456; SEEHAFER JR, 1981, ARCH DERMATOL, V117, P140, DOI 10.1001-archderm.117.3.140; Shapiro M, 2000, J AM ACAD DERMATOL, V42, P297, DOI 10.1016-S0190-9622(00)90146-4; Sharifian Maryam, 2011, Acta Dermatovenerol Alp Pannonica Adriat, V20, P51; Sharma R, 2012, Indian J Nephrol, V22, P45, DOI 10.4103-0971-4065.83743; SHETTAR SP, 1984, BRIT J RHEUMATOL, V23, P220; SHIOKAWA Y, 1977, ARTHRITIS RHEUM, V20, P1464, DOI 10.1002-art.1780200804; SHUTTLEWORTH D, 1985, CLIN EXP DERMATOL, V10, P392; SHUTTLEWORTH D, 1985, BRIT J DERMATOL, V113, P89, DOI 10.1111-j.1365-2133.1985.tb13058.x; Siafakas CG, 1998, AM J GASTROENTEROL, V93, P2544, DOI 10.1016-S0002-9270(98)00596-6; SIMPSON NB, 1979, ACTA DERM-VENEREOL, V59, P543; Squitti R, 2002, EUR J CLIN INVEST, V32, P51, DOI 10.1046-j.1365-2362.2002.00933.x; Steen VD, 2001, ARTHRITIS RHEUM, V44, P2828, DOI 10.1002-1529-0131(200112)44:122828::AID-ART4703.0.CO;2-U; STEEN VD, 1982, ANN INTERN MED, V97, P652; STERNLIEB I, 1981, Journal of Rheumatology, V7, P149; STOCKMAN A, 1986, J RHEUMATOL, V13, P269; Stork J, 1996, CLIN EXP RHEUMATOL, V14, P337; Sugita K, 2004, J Dermatolog Treat, V15, P214, DOI 10.1080-09546630410027805; Szegedi A, 2004, ACTA DERM-VENEREOL, V84, P318, DOI 10.1080-00015550410026399; Tandon M, 1974, POSTGRAD MED J S2, V50, P39; Tandon M, 2010, ACTA PAEDIATR, V99, P1324, DOI 10.1111-j.1651-2227.2010.01837.x; Tchebiner JZ, 2002, ANN PHARMACOTHER, V36, P444, DOI 10.1345-aph.1A229; THOMAS RHM, 1985, CLIN EXP DERMATOL, V10, P386; THOMAS RHM, 1984, J ROY SOC MED, V77, P794; Toth GG, 1999, BRIT J DERMATOL, V141, P583; Tovaru S, 2010, J PERIODONTOL, V81, P1231, DOI 10.1902-jop.2010.090736; TROY JL, 1981, J AM ACAD DERMATOL, V4, P547; VANDESTAAK WJBM, 1975, DERMATOLOGICA, V150, P372; WALSHE JM, 1956, AM J MED, V21, P487, DOI 10.1016-0002-9343(56)90066-3; WALSHE JM, 1979, LANCET, V2, P144; WALSHE J M, 1981, Journal of Rheumatology, V7, P155; Walshe JM, 1968, POSTGRAD MED J S, P6; WARING RH, 1988, XENOBIOTICA, V18, P235; WEIGERT WM, 1975, ANGEW CHEM INT EDIT, V14, P330, DOI 10.1002-anie.197503301; Weller R, 1998, ANN PHARMACOTHER, V32, P1368, DOI 10.1345-aph.18099; Weller R, 1996, CLIN EXP DERMATOL, V21, P121, DOI 10.1046-j.1365-2230.1996.d01-185.x; WOLF R, 1994, DERMATOLOGY, V189, P1; ZONE J, 1982, Journal of the American Medical Association, V247, P2705, DOI 10.1001-jama.247.19.270546
Doença Pulmonar Obstrutiva Crônica e Transtornos de Deglutição: revisão de literatura
No full textTCC(graduação) - Universidade Federal de Santa Catarina. Centro de Ciências da Saúde. Fonoaudiologia.Introdução: Pelas projeções dos órgãos de saúde e sociedades científicas da área, nas próximas décadas a DPOC será uma das cinco primeiras causas de morte em todo o mundo sendo que no Brasil já é uma das doenças mais incapacitantes e com elevados índices de mortalidade. A DPOC corresponde a presença de obstrução ou limitação crônica do fluxo aéreo, apresentando progressão lenta e irreversível. A respiração é a parte intrínseca e vital no processo de deglutição, porém, é a função mais afetada na DPOC. Objetivo:Realizar uma revisão de literatura visando encontrar artigos que busquem a relação da Doença Pulmonar Obstrutiva Crônica com transtornos de deglutição.Metodologia:Foi conduzida uma busca em artigos nos idiomas PORTUGUES, INGLES e ESPANHOL sobre a relação da Doença Pulmonar Obstrutiva Crônica com transtornos de deglutição, sem limite de tempo, texto na íntegra, tipo de estudo (sem delimitação), população-alvo (adultos) nas bases de dados MEDLINE-PUBMED, LILACS, SCIELO e SCOPUS. As palavras-chave usadas isoladas e em cruzamentos foram: em português: DPOC; transtornos de deglutição, deglutição, disfagia e disfagia orofaríngea; em inglês: COPD, deglutition disorders, swallowing disorders, dysphagia e em espanhol: EPOC e transtornos de Deglución. Resultados: A pesquisa resultou em 224 artigos, destes apenas 18 preencheram os critérios de inclusão, sendo 12 artigos encontrados na base de dados PUBMED, 3 artigos encontrados na base de dados LILACS e 3 na base SCIELO. Conclusão: Há escassez de trabalhos sobre a correlação entre disfagia no paciente com DPOC, porém, em 15 (quinze) dos 18 (dezoito) artigos estudados, o que corresponde a 79% do total, houve esta relação. Sugerem-se novos estudos, estruturados metodologicamente, abordando este mesmo tema, para a disseminação do conhecimento a cerca dos fatores que podem influenciar a estabilidade do paciente acometido por estas comorbidades.Introduction: According to projections of health agencies and scientific societies of the area in the coming decades COPD is one of the five leading causes of death worldwide and in Brazil is already one of the most disabling diseases and high mortality. COPD accounts for obstruction or chronic airflow limitation, with slow progression and irreversible. Breathing is a vital and intrinsic part of the swallowing process, however, is the most affected function in COPD. Objective:To review the literature in order to find articles that seek the relationship of Chronic Obstructive Pulmonary Disease with swallowing disorders. Methods: We conducted a search for articles in languages PORTUGUESE, ENGLISH and SPANISH on the relationship of Chronic Obstructive Pulmonary Disease with swallowing disorders, no time limit, full text, type of study (without boundary), the target population (adults ) in MEDLINE, PUBMED, LILACS, SCIELO and SCOPUS. The keywords used were isolated and crossings: in Portuguese: COPD; swallowing disorders, swallowing, dysphagia and oropharyngeal dysphagia, in English: COPD, deglutition disorders, swallowing disorders, dysphagia and Spanish: EPOC and disorders Deglución. Results:The search resulted in 224 articles, of which only 18 met the inclusion criteria, 12articles found in PUBMED database, 3 articles found in the database LILACS and SCIELO third base. In SCOPUS database items found were discarded due to the exclusion criteria. Conclusion:There are few studies on the correlation between dysphagia in patients with COPD, however, within fifteen (15) of the eighteen (18) items studied, which corresponds to 79% of the total, there was this relationship. Suggest new studies, methodologically structured, addressing the same subject, for the dissemination of knowledge about the factors that may influence the stability of patients affected by these comorbidities
Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model
No full textVirus-like particles (VLPs) based on the small envelope protein of hepatitis B virus (HBsAg-S) are immunogenic at the B-and T-cell level. In this study, we inserted overlapping sequences encoding the carboxy terminus of the Helicobacter pylori katA gene product into HBsAg-S. The HBsAg-S-KatA fusion proteins were able to assemble into secretion-competent VLPs (VLP-KatA). The VLP-KatA proteins were able to induce KatA-specific antibodies in immunized mice. The mean total IgG antibody titers 41 days post-primary immunization with VLP-KatA (2.3 x 10(3)) were significantly greater (
- …
